US 12,421,320 B2
Protein S antibodies, methods of making and uses thereof
Sandip Panicker, South San Francisco, CA (US); Adam David Rosenthal, South San Francisco, CA (US); Tony Sang Young Byun, South San Francisco, CA (US); and Quehuong Thi Dong, South San Francisco, CA (US)
Assigned to Vega Therapeutics, Inc., South San Francisco, CA (US)
Filed by Vega Therapeutics, Inc., South San Francisco, CA (US)
Filed on Aug. 27, 2024, as Appl. No. 18/817,152.
Application 18/817,152 is a division of application No. 18/506,872, filed on Nov. 10, 2023, granted, now 12,145,999.
Application 18/506,872 is a continuation of application No. 17/923,503, previously published as PCT/US2021/030900, filed on May 5, 2021.
Claims priority of provisional application 63/169,755, filed on Apr. 1, 2021.
Claims priority of provisional application 63/020,505, filed on May 5, 2020.
Prior Publication US 2024/0425613 A1, Dec. 26, 2024
Int. Cl. C07K 16/36 (2006.01); A61K 47/68 (2017.01); A61P 7/04 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/36 (2013.01) [A61K 47/6843 (2017.08); A61P 7/04 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/32 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 21 Claims
 
1. A method of prophylactically treating a bleeding disorder in a subject in need thereof, comprising administering to the subject an antibody that binds Protein S, wherein the bleeding disorder is selected from the group consisting of hemophilia A, hemophilia B, von Willebrand disease (vWD) disease, menorrhagia, Factor I deficiency, Factor II deficiency, Factor VII deficiency, Factor XI deficiency, Factor VIII deficiency, Factor IX deficiency, trauma, and hereditary hemorrhagic telangiectasia, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), and wherein the VH and VL comprise a combination of six complementarity determining regions (CDRs), whose amino acid sequences are selected from the group consisting of:
a. a CDR-L1 comprising the sequence of SEQ ID NO: 1, a CDR-L2 comprising an amino acid sequence of QNS, a CDR-L3 comprising the sequence of SEQ ID NO: 24, a CDR-H1 comprising the sequence of SEQ ID NO: 36, a CDR-H2 comprising the sequence of SEQ ID NO: 48, and a CDR-H3 comprising the sequence of SEQ ID NO: 60; and
b. a CDR-L1 comprising the sequence of SEQ ID NO: 10, a CDR-L2 comprising an amino acid sequence of DAS, a CDR-L3 comprising the sequence of SEQ ID NO: 31, a CDR-H1 comprising the sequence of SEQ ID NO: 43, a CDR-H2 comprising the sequence of SEQ ID NO: 55, and a CDR-H3 comprising the sequence of SEQ ID NO: 67.